Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection News-Medical.net Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tacrolimus ... Astellas Submits US New Drug Application for Tacrolimus Extended Release ... |
